Uomi Cancer Center-Clinica Tres Torres

Barcelona 08017

5 studies enrolling now · 6 studies all time

What they study most

ALK-positive Non-small Cell Lung Cancer (NSCLC), Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Locally Advanced Solid Tumor, Metastatic Head-and-neck Squamous-cell Carcinoma, Metastatic Solid Tumor, Non Small Cell Lung Cancer, ROS1-positive Non-Small Cell Lung Cancer (NSCLC), Recurrent Head and Neck Squamous Cell Carcinoma

Studies at this site

• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer — Recruiting now
• A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma — Recruiting now
• A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) — Recruiting now
• Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors — Available (expanded access)
• Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors — Available (expanded access)
• A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer — Running, not enrolling